Study: Chemotherapy to Treat Breast Cancer Increases Risk of Lung Cancer
Pharmacy Times
APRIL 19, 2024
Individuals treated with chemotherapy following a breast cancer diagnosis were more at risk of developing second primary lung cancer.
Chemotherapy Related Topics 
Researchers Identify Chemotherapy Resistance Biomarkers in Triple-Negative Breast Cancer
Pharmacy Times
SEPTEMBER 2, 2022
DNA and RNA sequencing could provide insight about resistance to chemotherapy in patients suffering from triple-negative breast cancer.
Chemotherapy 
147
147 Chemotherapy 147
147 Join 5,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Pharmacist Follow-up Improves Patient Quality of Life After Emetogenic Chemotherapy
Drug Topics
NOVEMBER 8, 2022
Follow-ups from pharmacists show a significant increase in outpatient antiemetic drugs prescribed and quality of life in patients experiencing chemotherapy-induced nausea and vomiting.
Chemotherapy 144
144 Chemotherapy 144
144 
Drug Shortages in Community Oncology: Ensuring Access to Chemotherapy
Pharmacy Times
JUNE 17, 2024
Persistent chemotherapy drug shortages challenge oncology providers. American Oncology Network employs a drug shortage committee for organized shortage management that involves pharmacists and interdisciplinary stakeholders.
Chemotherapy 117
117 Chemotherapy 117
117 
What the FDA's New Dosage Guidance Means for the Future of Clinical Research
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
This new guidance will clearly impact the clinical research field, but how?
Cisplatin-Based Chemotherapy Linked to Hearing Loss in Cancer Survivors
Pharmacy Times
JULY 10, 2024
Extended treatment with high doses of cisplatin-based chemotherapy is associated with severe and progressive hearing loss.
Chemotherapy 117
117 Chemotherapy 117
117 
New chemotherapy treatment could benefit multiple cancer types
European Pharmaceutical Review
FEBRUARY 15, 2024
A clinical trial in malignant pleural mesothelioma (MPM) has demonstrated the first successful combination of chemotherapy with a drug targeting cancer’s metabolism developed for the asbestos-induced disease in two decades. The anti-cancer treatment combines the new drug ADI-PEG20 and traditional chemotherapy.
Chemotherapy 105
105 Chemotherapy 105
105 
FDA approves J&J’s Rybrevant with chemotherapy for NSCLC treatment
Pharmafile
MARCH 4, 2024
The drug has been approved in combination with chemotherapy (carboplatin-pemetrexed) for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 […] The post FDA approves J&J’s Rybrevant with chemotherapy for NSCLC treatment appeared (..)
Chemotherapy 110
110 
The DETECT V Trial: Exploring Chemotherapy-Free Treatment for HER2+/HR+ Metastatic Breast Cancer
Pharmacy Times
SEPTEMBER 16, 2024
Data from the second interim analysis of the DETECT V trial, presented at ESMO Congress 2024, suggest that a chemotherapy-free regimen combining dual HER2-targeted therapy with endocrine therapy, particularly with the addition of ribociclib, may be an effective treatment for patients.
Chemotherapy 124
124 Chemotherapy 124
124 
Novel device opens blood-brain barrier to deliver chemotherapy
European Pharmaceutical Review
MAY 3, 2023
The blood-brain barrier (BBB) in glioblastoma patients was opened temporarily using a novel, skull-implantable ultrasound device to deliver chemotherapy to the brain in a first in-human trial. Two chemotherapy drugs , paclitaxel and carboplatin were injected intravenously during the four-minute procedure.
Chemotherapy 119
119 Chemotherapy 119
119 
FDA Approves Nivolumab Plus Chemotherapy for Unresectable or Metastatic Urothelial Carcinoma
Drug Topics
MARCH 8, 2024
A clinical trial showed that nivolumab plus chemotherapy significantly improved overall survival and progression-free survival compared with a chemotherapy combination alone.
Chemotherapy 98
98 
AstraZeneca’s Tagrisso plus chemotherapy wins EU approval for NSCLC
Pharmaceutical Technology
JULY 5, 2024
Approval is based on positive data from the Phase III FLAURA2 trial where Tagrisso plus chemotherapy showed PFS of 24.4
Chemotherapy 98
98 Chemotherapy 98
98 
FDA Approves Tislelizumab-jsgr for Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy
Pharmacy Times
MARCH 14, 2024
Results from the phase 3 RATIONALE 302 trial showed tislelizumab-jsgr prolonged survival compared to chemotherapy in patients who received prior systemic treatment.
Chemotherapy 110
110 
As Chemotherapy Drug Shortage Continues, Unimaginable Decisions and Lacking Accountability Reign
Pharmacy Times
JULY 24, 2023
Treatment providers have been forced to adapt and make potentially life-altering decisions for patients due to persistent chemotherapy drug shortages, all while solutions from the FDA and drug manufacturers remain scant.
Chemotherapy 112
112 
Atorvastatin shown to reduce cardiac dysfunction in anthracycline-based chemotherapy
Hospital Pharmacy Europe
AUGUST 10, 2023
The use of atorvastatin prior to anthracycline-based chemotherapy in lymphoma patients reduces the subsequent development of cardiac dysfunction, according to the findings of a randomised trial. The post Atorvastatin shown to reduce cardiac dysfunction in anthracycline-based chemotherapy appeared first on Hospital Pharmacy Europe.
Chemotherapy 97
97 
FDA Accepts sBLA for Dostarlimab With Chemotherapy to Treat Endometrial Cancer
Pharmacy Times
APRIL 25, 2024
Dostarlimab plus chemotherapy is the only immuno-oncology-based therapy that showed statistically significant and clinically meaningful survival benefit in the overall patient population.
Chemotherapy 98
98 
Nivolumab-Chemotherapy Combination Lengthens Survival, Causes Manageable Adverse Effects in Stage III or IV Classic Hodgkin Lymphoma
Pharmacy Times
OCTOBER 17, 2024
Compared with brentuximab vedotin and chemotherapy, nivolumab and chemotherapy had longer progression-free survival and a better safety profile.
Chemotherapy 99
99 Chemotherapy 99
99 
Non-chemotherapy lymphoma treatment may provide durable remission
European Pharmaceutical Review
JUNE 19, 2024
A non-chemotherapy multi-drug therapy enabled complete remission in 38 percent of evaluable patients with aggressive B-cell lymphoma, a Phase Ib/II clinical trial shows. The post Non-chemotherapy lymphoma treatment may provide durable remission appeared first on European Pharmaceutical Review.
Chemotherapy 98
98 Chemotherapy 98
98 
Chemotherapy prescribing habits for stage 3 colon cancer changed following IDEA study
Hospital Pharmacy Europe
AUGUST 14, 2023
A significant and increasing trend towards the use of a three-month rather than six-month adjuvant chemotherapy regime in stage 3 colon cancer has been observed following publications from the IDEA collaboration abstract. In addition, CAPOX prescribing also significantly increased from 14% to 48% (p <0.001).
Chemotherapy 97
97 
High BMI in Breast Cancer Patients Linked With Increased Cardiotoxicity During Chemotherapy
Drug Topics
AUGUST 9, 2023
A recent study being presented at the American College of Cardiology Latin America 2023 conference found the prevalence of cardiotoxicity among patients with breast cancer undergoing chemotherapy was 11.94%.
Chemotherapy 98
98 Chemotherapy 98
98 
Combining Keytruda And Chemo May Improve Survival in Advanced Endometrial Cancer
Drug Topics
MAY 8, 2023
Patients with advanced or recurrent endometrial cancer treated with Keytruda plus chemotherapy had improved progression-free survival compared with chemotherapy alone.
Chemotherapy 187
187 Chemotherapy 187
187 
Durvalumab With Chemotherapy Shows Long-Term Overall Survival at 3 Years
Pharmacy Times
APRIL 18, 2024
The results were the longest survival follow-up ever reported for a phase 3 trial for biliary tract cancer.
Chemotherapy 136
136 Chemotherapy 136
136 
Blinatumomab Plus Chemotherapy Improves DFS in Pediatric Patients With SR B-ALL
Pharmacy Times
DECEMBER 7, 2024
In newly diagnosed average and high standard risk B-cell acute lymphoblastic leukemia (B-ALL), blinatumomab improved disease-free survival (DFS) by approximately 97.5% and 94.1%, respectively.
Chemotherapy 120
120 Chemotherapy 120
120 
STAT+: Hair loss is one of the most hated chemotherapy side effects. A new biotech hopes to prevent it
STAT
JANUARY 17, 2024
The chemotherapy Christine Ko was prescribed for her breast cancer is pretty much a guarantee for losing your hair. The company is currently developing an antibody that might reliably protect the head’s hair follicles from chemotherapy damage — if it works. But, to her, it wasn’t much of an option.
Chemotherapy 93
93 Chemotherapy 93
93 
STAT+: Drug may make chemotherapies less effective in cancer patients with obesity — but many doctors are in the dark
STAT
OCTOBER 28, 2024
This means chemotherapies may be less effective when interacting with the medicine, but some clinicians, and their patients, are unaware of that possibility. A drug used to combat fungal infections in cancer patients comes with a big caveat — research shows the medicine can last twice as long as in people with obesity.
Chemotherapy 106
106 
FDA Approves Pembrolizumab Plus Pemetrexed and Platinum Chemotherapy for Malignant Pleural Mesothelioma
Pharmacy Times
SEPTEMBER 18, 2024
The approval is based on positive results from the phase 2/3 IND.227/KEYNOTE-483 227/KEYNOTE-483 trial.
Chemotherapy 132
132 
'We can't forget about this': As chemotherapy shortage ebbs and flows, attention shifts to long-term solutions
Fierce Pharma
SEPTEMBER 27, 2023
It’s been about 10 months since FDA inspectors rebuked a | As some cancer centers struggle to secure access to key platinum-based chemotherapies, a national spotlight gives the issue newfound political importance. But will this be a turning point for the recurrent shortage issue? ASCO's Julie Gralow, M.D., certainly hopes so.
Chemotherapy 94
94 
Women Treated for Breast Cancer Experience Accelerated Biological Aging
Drug Topics
JULY 25, 2023
Radiation therapy was associated with the largest increase, compared to chemotherapy or endocrine therapies.
Chemotherapy 187
187 Chemotherapy 187
187 
High-Dose Vitamin C Improves Outcomes for Late-Stage Pancreatic Cancer
Pharmacy Times
DECEMBER 3, 2024
High-dose vitamin C, when combined with chemotherapy, has shown the potential to double the survival rate of patients with late-stage metastatic pancreatic cancer.
Chemotherapy 148
148 Chemotherapy 148
148 
Topical Minoxidil Improves Hair Growth in 87% of Pediatric Patients With Chemotherapy-Induced Alopecia
Pharmacy Times
MARCH 18, 2024
The FDA-approved topical and oral agent is currently indicated for adult patients with patterned alopecia.
Chemotherapy 129
129 
Tislelizumab Demonstrates Superior Overall Survival Compared With Chemotherapy
Pharmacy Times
APRIL 24, 2023
Efficacy and safety data for BeiGene’s therapy shows positive results for individuals with advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
Chemotherapy 111
111 Chemotherapy 111
111 
European Commission approves combination chemotherapy for treatment of advanced EGFR-mutated non-small cell lung cancer in adult patients
Pharmafile
AUGUST 27, 2024
Today, Janssen-Cilag International, part of Johnson & Johnson (J&J) has announced that the European Comission (EC) has approved a combined treatment of rybrevant (amivantamab) and chemotherapy (carboplatin and pemerexed) for the treatment of non-small cell lung cancer (NSCLC) with an epidermal growth factor receptor (EGFR).
Chemotherapy 69
69 Chemotherapy 69
69 
Personalized Survivorship Plans for Colon Cancer Patients Receiving Adjuvant Chemotherapy
Drug Topics
OCTOBER 23, 2023
Survivorship care for patients with colon cancer should include comprehensive coordination between oncologists, specialists, and primary care providers and include psychological and economic factors in addition to standard health recommendations.
Chemotherapy 112
112 Chemotherapy 112
112 
FDA Approves Osimertinib With Chemotherapy for EGFRm NSCLC
Pharmacy Times
FEBRUARY 19, 2024
Osimertinib was previously approved as a monotherapy, the first-in-line global standard of care, for non–small cell lung cancer indications.
Chemotherapy 91
91 
Researchers Find “Digital Twin” Model Accurately Predicts Treatment Responses for Different Chemotherapy Drugs
Pharmacy Times
OCTOBER 30, 2024
This model, which uses technology that discovers black holes, pulls from real data to evaluate cancer treatments, optimizing treatment choices for patients with different cancers.
Chemotherapy 102
102 Chemotherapy 102
102 
FDA Approves Pembrolizumab With Chemotherapy to Treat Adult Patients With Endometrial Carcinoma
Pharmacy Times
JUNE 18, 2024
The indication is for adult patients with primary advanced or recurrent endometrial carcinoma and is the third indication that pembrolizumab has received for this disease state.
Chemotherapy 97
97 
FDA Expands Approval of Dostarlimab-Gxly Plus Chemotherapy to All Adults With Primary, Recurrent Endometrial Cancer
Pharmacy Times
AUGUST 1, 2024
The RUBY trial will continue and analyze the overall population survival after treatment with the drug combination.
Chemotherapy 111
111 
FDA Approves Nivolumab for the Treatment of Adult Patients With Resectable NSCLC
Pharmacy Times
OCTOBER 4, 2024
Nivolumab is the only PD-1 inhibitor to show statistically significant and clinically meaningful benefits in non-small cell lung cancer compared with chemotherapy.
Chemotherapy 127
127 
FDA Approves Durvalumab for Treatment of Adults Patients With LS-SCLC
Pharmacy Times
DECEMBER 5, 2024
The indication is for adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed after platinum-based chemotherapy and radiation therapy.
Chemotherapy 112
112 
AstraZeneca’s Tagrisso receives approval in Japan for lung cancer
Pharmaceutical Technology
JUNE 26, 2024
AstraZeneca has received Japanese approval for Tagrisso plus chemotherapy as first-line treatment for non-small cell lung cancer (NSCLC).
Chemotherapy 125
125 Chemotherapy 125
125 
Tagrisso-chemo cleared in US as 1st-line lung cancer therapy
pharmaphorum
FEBRUARY 19, 2024
AstraZeneca’s Tagrisso is cleared by FDA for use alongside chemotherapy as a frontline therapy for EGFR-positive lung cancer (NSCLC)
Chemotherapy 124
124 
AstraZeneca’s Tagrisso approved in Japan for lung cancer treatment
Pharmafile
JUNE 25, 2024
AstraZeneca has announced that Tagrisso (osimertinib) in combination with pemetrexed and platinum-based chemotherapy has been approved in Japan for the first line treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) whose tumours have exon 19 deletions or (..)
Chemotherapy 119
119 Chemotherapy 119
119 
Genetic Insights in Taxane-Related Nerve Damage for Breast Cancer Survivors
Pharmacy Times
JULY 16, 2024
Prediction model can accurately predict the risk of nerve damage in patients who received taxane-based chemotherapy.
Chemotherapy 121
121 Chemotherapy 121
121 
Nivolumab Combination Regimen Improved Survival of Patients with Bladder Cancer By A Third Compared to Chemotherapy Alone
Pharmacy Times
OCTOBER 24, 2023
The novel combination met the co-primary endpoints of progression-free survival and overall survival during the CheckMate -901 trial, also demonstrating sizeable improvement in objective response.
Chemotherapy 115
115 Chemotherapy 115
115 
Let's personalize your content